Ocular health comparable to wearing no contact lens

Article

Study shows that patients wearing 1-Day Acuvue TruEye lenses exhibit no clinically significant differences as compared to spectacle wearers after a year of lens wear.

 

Jacksonville, FL-Daily disposable silicone hydrogel contact lenses (narafilcon A) show no clinically significant effect on the ocular surface of the eye, according to a recent study. The findings were published in the June issue of Contact Lens & Anterior Eye.

The 74-subject, investigator-masked, parallel group study compared patients with no previous contact lens experience, randomized to wear narafilcon A (1-Day Acuvue TruEye) with patients who had not previously worn contact lenses and kept wearing their own spectacles for 12 months. Biomicroscopy, visual acuity, and subjective response scores were recorded at an initial visit and 6 follow-up visits, in addition to lens fit and surface evaluation for the LW group. Comfort was recorded with text messaging.

After a full year of wear, there were no clinically significant differences between contact lens wearers and spectacle wearers for 5 out of 6 key ocular health measures: bulbar conjunctival hyperemia, limbal hyperemia, corneal staining, neovascularization, and papillary conjunctivitis. There was more conjunctival staining for contact lens wearers than spectacle wearers, although grades were low averaging only “trace” levels throughout the study. Subjective scores were similar for the two groups. Measured visual acuity was approximately half a line better for spectacle wearers because these subjects were provided with their full sphero-cylindrical over-refraction, compared with contact lens wearers in the best spherical corrected contact lenses.

The study was sponsored by Vistakon Division of Johnson & Johnson Vision Care Inc.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
© 2025 MJH Life Sciences

All rights reserved.